Drug intelligence / Profile preview

ALG-127563

Development stage: Preclinical
Lead developer: Aligos Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

ALG-127563 is a second-generation, GalNAc-conjugated small interfering RNA (siRNA) developed by Aligos Therapeutics for the treatment of chronic hepatitis B (CHB) and chronic hepatitis D (CHD). It is designed to target the hepatitis B virus (HBV) genome to inhibit the release of hepatitis B surface antigen (HBsAg). In preclinical studies, ALG-127563 demonstrated improved in vitro and in vivo potency, enhanced stability in liver homogenates, and optimized binding to the asialoglycoprotein receptor (ASGR) compared to its predecessor, ALG-125755, and other clinical-stage siRNAs.

Beyond the preview

Go deeper on ALG-127563.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALG-127563.